Regulatory
AbbVie’s Maviret (glecaprevir/pibrentasvir) Receives EC’s Marketing Authorization as Eight-Week Regimen
Shots: The approval is based on P-IIIb EXPEDITION-8 study assessing Maviret in 343 treatment naïve chronic HCV patients with compensated cirrhosis across all major genotypes (GT1-6) for 8wks. The P-IIIb […]readmore
